Diabetic Neuropathy: Drug having disease-modifying potential will earn 40% patient share in the U.S

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of diabetic neuropathy, a drug that has disease-modifying potential would earn 40 percent patient share in the U.S., according to surveyed U.S. neurologists. Similarly, in Europe, such a drug would earn a comparable patient share of 43 percent, according to surveyed European neurologists.

"Interviewed experts told us that there is a great need for disease-modifying agents that can slow or reverse the progression of diabetic neuropathy. They note that currently available drugs focus on alleviating the painful symptoms and that there are no medications to treat the nonpainful symptoms of the disease," stated Decision Resources Analyst Christine Helliwell, Ph.D. "Therefore, an agent that fulfills such a need has the potential to achieve great commercial success in the U.S. and Europe."

The new report entitled Diabetic Neuropathy: Significant Opportunity Awaits Agents That Have Disease Modification Potential also finds that CNSBio's CNSB-001 will earn Decision Resources' proprietary clinical gold standard in 2013, following its approval for the indication in 2012. CNSB-001 has competitive advantages over the current gold standard, tramadol ER (Ortho-McNeil's Ultram ER, Labopharm's Tramadolor/Unitrama/Dolpar/Tridural, generics), in safety and tolerability.

"Although neither CNSB-001 or tramadol ER have disease-modifying capabilities, they earn our clinical gold-standard status because they are efficacious at reducing pain. According to neurologists we surveyed, reduction of pain is the attribute they consider most important in a diabetic neuropathy drug," added Dr. Helliwell.

SOURCE Decision Resources


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Research probes interaction between SARS-CoV-2 and influenza